share_log

Nxera Pharma Receives US$10 Million From AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

Nxera Pharma Receives US$10 Million From AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone

Nxera Pharma收到艾伯维公司1亿美元,因针对神经疾病的合作达成首个研发里程碑。
Sosei Group ·  06/26 11:00
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发